270 related articles for article (PubMed ID: 22920396)
1. The clinically relevant pharmacogenomic changes in acute myelogenous leukemia.
Emadi A; Karp JE
Pharmacogenomics; 2012 Aug; 13(11):1257-69. PubMed ID: 22920396
[TBL] [Abstract][Full Text] [Related]
2. A 2-gene classifier for predicting response to the farnesyltransferase inhibitor tipifarnib in acute myeloid leukemia.
Raponi M; Lancet JE; Fan H; Dossey L; Lee G; Gojo I; Feldman EJ; Gotlib J; Morris LE; Greenberg PL; Wright JJ; Harousseau JL; Löwenberg B; Stone RM; De Porre P; Wang Y; Karp JE
Blood; 2008 Mar; 111(5):2589-96. PubMed ID: 18160667
[TBL] [Abstract][Full Text] [Related]
3. Multi-institutional phase 2 clinical and pharmacogenomic trial of tipifarnib plus etoposide for elderly adults with newly diagnosed acute myelogenous leukemia.
Karp JE; Vener TI; Raponi M; Ritchie EK; Smith BD; Gore SD; Morris LE; Feldman EJ; Greer JM; Malek S; Carraway HE; Ironside V; Galkin S; Levis MJ; McDevitt MA; Roboz GR; Gocke CD; Derecho C; Palma J; Wang Y; Kaufmann SH; Wright JJ; Garret-Mayer E
Blood; 2012 Jan; 119(1):55-63. PubMed ID: 22001391
[TBL] [Abstract][Full Text] [Related]
4. Pharmacogenomics and the treatment of acute myeloid leukemia.
Megías-Vericat JE; Montesinos P; Herrero MJ; Bosó V; Martínez-Cuadrón D; Poveda JL; Sanz MÁ; Aliño SF
Pharmacogenomics; 2016 Jul; 17(11):1245-1272. PubMed ID: 27381050
[TBL] [Abstract][Full Text] [Related]
5. Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia.
Jabbour E; Garcia-Manero G; Cortes J; Ravandi F; Plunkett W; Gandhi V; Faderl S; O'Brien S; Borthakur G; Kadia T; Burger J; Konopleva M; Brandt M; Huang X; Kantarjian H
Clin Lymphoma Myeloma Leuk; 2012 Aug; 12(4):244-51. PubMed ID: 22534616
[TBL] [Abstract][Full Text] [Related]
6. Current and emerging therapies for acute myeloid leukemia.
Robak T; Wierzbowska A
Clin Ther; 2009; 31 Pt 2():2349-70. PubMed ID: 20110045
[TBL] [Abstract][Full Text] [Related]
7. Daunorubicin and cytarabine for certain types of poor-prognosis acute myeloid leukemia: a systematic literature review.
Megías-Vericat JE; Martínez-Cuadrón D; Sanz MÁ; Poveda JL; Montesinos P
Expert Rev Clin Pharmacol; 2019 Mar; 12(3):197-218. PubMed ID: 30672340
[TBL] [Abstract][Full Text] [Related]
8. The outcomes of relapsed acute myeloid leukemia in children: Results from the Japanese Pediatric Leukemia/Lymphoma Study Group AML-05R study.
Moritake H; Tanaka S; Miyamura T; Nakayama H; Shiba N; Shimada A; Terui K; Yuza Y; Koh K; Goto H; Kakuda H; Saito A; Hasegawa D; Iwamoto S; Taga T; Adachi S; Tomizawa D
Pediatr Blood Cancer; 2021 Jan; 68(1):e28736. PubMed ID: 32991072
[TBL] [Abstract][Full Text] [Related]
9. Synergy between high-dose cytarabine and asparaginase in the treatment of adults with refractory and relapsed acute myelogenous leukemia--a Cancer and Leukemia Group B Study.
Capizzi RL; Davis R; Powell B; Cuttner J; Ellison RR; Cooper MR; Dillman R; Major WB; Dupre E; McIntyre OR
J Clin Oncol; 1988 Mar; 6(3):499-508. PubMed ID: 3162515
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic priming with decitabine followed by low dose idarubicin and cytarabine in acute myeloid leukemia evolving from myelodysplastic syndromes and higher-risk myelodysplastic syndromes: a prospective multicenter single-arm trial.
Zhou X; Mei C; Zhang J; Lu Y; Lan J; Lin S; Zhang Y; Kuang Y; Ren Y; Ma L; Wei J; Ye L; Xu W; Li K; Lu C; Jin J; Tong H
Hematol Oncol; 2020 Oct; 38(4):531-540. PubMed ID: 32469434
[TBL] [Abstract][Full Text] [Related]
11. Clinical heterogeneity under induction with different dosages of cytarabine in core binding factor acute myeloid leukaemia.
Wang B; Zhang J; Hua X; Li H; Wang Z; Yang B
Sci Rep; 2020 Jan; 10(1):685. PubMed ID: 31959790
[TBL] [Abstract][Full Text] [Related]
12. A strategy to reduce cumulative anthracycline exposure in low-risk pediatric acute myeloid leukemia while maintaining favorable outcomes.
Sabnis HS; Minson KA; Monroe C; Allen K; Metts JL; Cooper TM; Woods WG; Castellino SM; Keller FG
Leuk Res; 2020 Sep; 96():106421. PubMed ID: 32683126
[TBL] [Abstract][Full Text] [Related]
13. Idarubicin, cytarabine, and topotecan in patients with refractory or relapsed acute myelogenous leukemia and high-risk myelodysplastic syndrome.
Lee ST; Jang JH; Suh HC; Hahn JS; Ko YW; Min YH
Am J Hematol; 2001 Dec; 68(4):237-45. PubMed ID: 11754412
[TBL] [Abstract][Full Text] [Related]
14. A phase 1-2 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome.
Jabbour E; Kantarjian H; Ravandi F; Garcia-Manero G; Estrov Z; Verstovsek S; O'Brien S; Faderl S; Thomas DA; Wright JJ; Cortes J
Cancer; 2011 Mar; 117(6):1236-44. PubMed ID: 20960519
[TBL] [Abstract][Full Text] [Related]
15. GSTT1 and GSTM1 polymorphisms predict treatment outcome for acute myeloid leukemia: a systematic review and meta-analysis.
Xiao Q; Deng D; Li H; Ye F; Huang L; Zhang B; Ye B; Mo Z; Yang X; Liu Z
Ann Hematol; 2014 Aug; 93(8):1381-90. PubMed ID: 24994605
[TBL] [Abstract][Full Text] [Related]
16. Polymorphisms at microRNA binding sites of Ara-C and anthracyclines-metabolic pathway genes are associated with outcome of acute myeloid leukemia patients.
Cao HX; Miao CF; Yan L; Tang P; Zhang LR; Sun L
J Transl Med; 2017 Nov; 15(1):235. PubMed ID: 29141648
[TBL] [Abstract][Full Text] [Related]
17. CPX-351 daunorubicin-cytarabine liposome: a novel formulation to treat patients with newly diagnosed secondary acute myeloid leukemia.
Cafaro A; Giannini MB; Silimbani P; Cangini D; Masini C; Ghelli Luserna Di Rorà A; Simonetti G; Martinelli G; Cerchione C
Minerva Med; 2020 Oct; 111(5):455-466. PubMed ID: 32955826
[TBL] [Abstract][Full Text] [Related]
18. Clinical Impact of Additional Cytogenetic Aberrations, cKIT and RAS Mutations, and Treatment Elements in Pediatric t(8;21)-AML: Results From an International Retrospective Study by the International Berlin-Frankfurt-Münster Study Group.
Klein K; Kaspers G; Harrison CJ; Beverloo HB; Reedijk A; Bongers M; Cloos J; Pession A; Reinhardt D; Zimmerman M; Creutzig U; Dworzak M; Alonzo T; Johnston D; Hirsch B; Zapotocky M; De Moerloose B; Fynn A; Lee V; Taga T; Tawa A; Auvrignon A; Zeller B; Forestier E; Salgado C; Balwierz W; Popa A; Rubnitz J; Raimondi S; Gibson B
J Clin Oncol; 2015 Dec; 33(36):4247-58. PubMed ID: 26573082
[TBL] [Abstract][Full Text] [Related]
19. Daunorubicin and Cytarabine Liposome in Newly Diagnosed Therapy-Related Acute Myeloid Leukemia (AML) or AML With Myelodysplasia-Related Changes.
Kim M; Williams S
Ann Pharmacother; 2018 Aug; 52(8):792-800. PubMed ID: 29532662
[TBL] [Abstract][Full Text] [Related]
20. Response-guided chemotherapy for pediatric acute myeloid leukemia without hematopoietic stem cell transplantation in first complete remission: Results from protocol DB AML-01.
De Moerloose B; Reedijk A; de Bock GH; Lammens T; de Haas V; Denys B; Dedeken L; van den Heuvel-Eibrink MM; Te Loo M; Uyttebroeck A; Van Damme A; Van der Werff-Ten Bosch J; Zsiros J; Kaspers G; de Bont E
Pediatr Blood Cancer; 2019 May; 66(5):e27605. PubMed ID: 30623572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]